Procurement Summary
Country: Finland
Summary: Extensive Pharmacogenetic Panel, Islab
Deadline: 31 Dec 2025
Posting Date: 30 Nov 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 131175106
Document Ref. No.: 572944
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
The object of the acquisition is the Islab wellness company's extensive pharmacogenetic panel. The results of the panel are forwarded to ISLAB via HL7 connection and a statement in Finnish is given on the results of the panel. A broad pharmacogenetic panel refers to a gene panel, where more than 12 clinically significant genes affecting drug therapy are studied. The results and statement must be compatible with Kanta archiving. The acquisition complements the possibilities of ISLAB's customers to acquire pharmacogenetic studies. The estimated annual research volume is 400, which is based on the research volumes of previous years. The customer does not have a quantity purchase obligation, but the estimated amount is given to make the offer easier. The procurement contract period begins on February 1, 2026. The deal is valid indefinitely with six (6) months' notice. In procurement, 1 supplier is selected using an open procedure.
Published:30/11/2025 Deadline for submitting questions:17/12/2025 Deadline for tenders:31/12/2025
Documents
Tender Notice